uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Is cyclin A a prognostic factor in node negative breast cancer?
Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
Show others and affiliations
Manuscript (Other academic)
URN: urn:nbn:se:uu:diva-97141OAI: oai:DiVA.org:uu-97141DiVA: diva2:171946
Available from: 2008-04-29 Created: 2008-04-29 Last updated: 2010-01-13Bibliographically approved
In thesis
1. Cyclin A and cyclin E as prognostic factors in early breast cancer
Open this publication in new window or tab >>Cyclin A and cyclin E as prognostic factors in early breast cancer
2008 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Breast cancer is one of the most common malignancies in women. Due to early detection and the use of screening programs approximately 60% of all new cases lack lymph node involvement. Today, a substantial proportion of these women will be offered adjuvant systemic chemotherapy. However, better proliferation markers are needed to predict patient outcome and to avoid overtreatment.

Cyclin A, cyclin E and Ki-67 are all markers for proliferation and involved in the regulation of the cell cycle. Overexpression has been associated with disease recurrence in several studies, but the results have not been consistent. However, none of these studies has investigated aberrant expression of cyclin E (the expression of cyclin E during phases of the cell cycle other than late G1 and early S-phase). Studies have shown that aberrant cyclin E might provide additional prognostic information compared to cyclin E alone.

The aims of this thesis were 1.to investigate the prognostic value of cyclin A, cyclin E and aberrant cyclin E in early breast cancer. 2.to validate the tissue microarray (TMA) technique for cyclin A and 3.to define the most optimal cut-off values for cyclin A and Ki-67.

We found that the agreement of TMA and large section results was good with kappa values 0.62-0.75 and that the reproducibility of the two readers’ results was good or even very good, with kappa values 0.71 – 0.87.

The optimal cut-off value for cyclin A average was 8% and for cyclin A maximum value 11%. The corresponding values for Ki-67 were 15 and 22%.

Neither cyclin E nor aberrant cyclin E was a prognostic factor in low-risk node negative breast cancer patients.

Finally, we conclude that cyclin A is a prognostic factor in node negative breast cancer (univariate analysis average value OR=2.9 95% CI 1.8-4.6; maximum value OR=3.7 95% CI 2.3-5.9).

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2008. 57 p.
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 343
Oncology, breast cancer, chemotherapy, cyclin A, cyclin E, aberrant cyclin E, Ki-67, TMA, Onkologi
urn:nbn:se:uu:diva-8678 (URN)978-91-554-7181-1 (ISBN)
Public defence
2008-05-21, Wilandersalen, M-huset, Universitetssjukhuset Örebro, Örebro, 09:00
Available from: 2008-04-29 Created: 2008-04-29Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Oncology, Radiology and Clinical Immunology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 256 hits
ReferencesLink to record
Permanent link

Direct link